Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
08/10/2026 22:19
BRIEF-Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data Oct 8 (Reuters) - NovaBridge Biosciences NBP.O:
NOVABRIDGE BIOSCIENCES ANNOUNCES EXPANDED GIVASTOMIG SAFETY AND EFFICACY DATA TO BE PRESENTED AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 2026
Source text: ID:nGNX7zlwmj
Further company coverage: NBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview